Adaptimmune price target lowered to 46c from $1 at Barclays

Barclays analyst Peter Lawson lowered the firm’s price target on Adaptimmune (ADAP) to 46c from $1 and keeps an Underweight rating on the shares. The company’s Q1 product revenue was roughly in line with consensus but it evaluated strategic options ongoing to address its constrained capital position, the analyst tells investors in a research note.